As our understanding of the mechanisms of cancer treatment has increased, a growing
number of studies demonstrate pathways through which DNA damage repair (DDR) affects …

The standard treatment of ovarian cancer (OC) patients, including debulking surgery and
first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority …

Ovarian cancer (OC) has a high impact on morbidity and mortality in the female population.
Survival is modest after platinum progression. Therefore, the search for new therapeutic …

Cancer is a disease that induces many local and systemic changes in immunity. The difficult
nature of ovarian cancer stems from the lack of characteristic symptoms that contributes to a …

Breast cancer and gynecological tumors seriously endanger women's physical and mental
health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and …

Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based
chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic …

Background Endometrial cancer (EC) represents the sixth most common female tumor. In
the advanced setting, the prognosis is dismal with limited treatment options. Platinum-based …

The DNA damage response (DDR) pathway regulates DNA repair and cell survival, and
inactivating mutations in DDR genes can increase tumour mutational burden (TMB), a …

Purpose: Ovarian cancer is the most lethal gynecologic cancer and intrinsically resistant to
checkpoint immunotherapies. We sought to augment innate immunity, building on previous …

Simple Summary OV is the most lethal gynecological malignancy. M6A and lncRNAs have a
great impact on OV development and patient immunotherapy response. This study provided …